Literature DB >> 18059080

Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy.

Khalid Hussain1.   

Abstract

Hyperinsulinaemic hypoglycaemia is a cause of persistent hypoglycaemia in the neonatal and infancy periods. Prompt recognition and management of patients with hyperinsulinaemic hypoglycaemia are essential, if brain damage and long-term neurological sequelae are to be avoided. Hyperinsulinaemic hypoglycaemia can be transient, prolonged, or persistent (congenital). Advances in the fields of molecular biology, genetics, and pancreatic beta-cell physiology are beginning to provide novel insights into the mechanisms causing congenital forms of hyperinsulinism. So far mutations in six different genes have been described that lead to unregulated insulin secretion. The histological differentiation of focal and diffuse congenital hyperinsulinism has radically changed the surgical approach to this disease. Until recently, highly invasive investigations were performed to localize the focal lesion, but recent experience with (18)F-L-dopa positron emission tomography scanning suggests that this technique is highly sensitive for differentiating diffuse from focal disease as well as for accurately locating the focal lesion. Despite recent advances, the genetic basis of congenital hyperinsulinism is still unknown in about 50% of the patients, and the management of medically unresponsive diffuse disease remains a real challenge. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059080     DOI: 10.1159/000111789

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  28 in total

1.  Echocardiography monitoring for diazoxide induced pericardial effusion.

Authors:  Bindu Avatapalle; Indraneel Banerjee; Nilima Malaiya; Raja Padidela
Journal:  BMJ Case Rep       Date:  2012-07-03

Review 2.  Approach to hypoglycemia in infants and children.

Authors:  Kajal Gandhi
Journal:  Transl Pediatr       Date:  2017-10

3.  Delayed presentation of prolonged hyperinsulinaemic hypoglycaemia in a preterm small-for-gestational age neonate.

Authors:  Jin Ho Chong; Suresh Chandran; Prathibha Agarwal; Victor Samuel Rajadurai
Journal:  BMJ Case Rep       Date:  2013-12-18

Review 4.  Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

Authors:  Matthew R Timlin; Alexander B Black; Heather M Delaney; Renée I Matos; Candace S Percival
Journal:  Pediatr Cardiol       Date:  2017-06-22       Impact factor: 1.655

5.  Diazoxide-Induced Neutropenia and Long-Term Follow-up in a Patient with Hyperinsulinemia-Hyperammonemia due to GLUD1 Mutation.

Authors:  D Vuralli; S Aytac Eyupoglu; N Kandemir; A Ozon; N Gonc; A Alikasifoglu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

6.  Persistent hyperinsulinemic hypoglycemia of infancy: a clinical and pathological study of 19 cases in a single institution.

Authors:  Jiwei Li; Yangyang Ma; Mengxing Lv; Jun Zhou; Baihui Liu; Kuiran Dong; Xianmin Xiao; Lian Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide.

Authors:  Madeline L Keyes; Helen Healy; Katherine A Sparger; Lucas E Orth; Mayya Geha; Sergei Roumiantsev; Juan D Matute
Journal:  Pediatrics       Date:  2021-02       Impact factor: 7.124

8.  Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia.

Authors:  Elias Spanakis; Claudia Gragnoli
Journal:  Obes Surg       Date:  2009-06-24       Impact factor: 4.129

Review 9.  Hyperinsulinaemic hypoglycaemia:genetic mechanisms, diagnosis and management.

Authors:  Zainaba Mohamed; Ved Bhushan Arya; Khalid Hussain
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-10-02

10.  CRISPR/Cas9 ADCY7 Knockout Stimulates the Insulin Secretion Pathway Leading to Excessive Insulin Secretion.

Authors:  Yazeid Alhaidan; Henrik Thybo Christesen; Elena Lundberg; Mohammed A Al Balwi; Klaus Brusgaard
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.